A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting from Turkbio registry

Yazici, A.Isik, O. OzdemirKoca, S. S.Senel, S.Inanc, N.Akar, S.Yilmaz, S.Gunduz, O. SoysalCefle, A.Onen, F.2024-06-262024-06-262021-06-010003-4967https://doi.org/10.1136/annrheumdis-2021-eular.2928https://hdl.handle.net/11452/42398Bu çalışma, 02-05 Haziran 2021 tarihleri arasında düzenlenen Annual European Congress of Rheumatology (EULAR)’da bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/openAccessScience & technologyLife sciences & biomedicineRheumatologyRheumatologyA national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting from Turkbio registryMeeting Abstract0006926253002291140114180Supplement 110.1136/annrheumdis-2021-eular.2928